{"entity":{"id":"paper-fort-long-term-follow-up-hoskin-lancet-oncol-2021","kind":"paper","name":"FoRT long-term follow-up: 4 Gy versus 24 Gy for follicular and marginal zone lymphoma","aka":[],"tldr":"Five years on, the higher radiotherapy dose still controlled indolent lymphoma far better: 90 percent of treated sites were free of regrowth after 24 Gy against 70 percent after 4 Gy.","summary":"Long-term follow-up of the FoRT trial (614 target sites in 548 patients) at a median of 73.8 months: 117 local progression events, 27 after 24 Gy and 90 after 4 Gy.\n\nLocal progression-free rates were 94.1 percent at two years and 89.9 percent at five years after 24 Gy against 79.8 and 70.4 percent after 4 Gy (hazard ratio 3.46).","asOf":"2026-09-22","links":[{"label":"Lancet Oncol 2021","url":"https://doi.org/10.1016/S1470-2045(20)30686-0"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/33539729/"}],"tags":[],"related":[],"cancers":["follicular-lymphoma","marginal-zone-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["fort"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["lancet-oncology"],"dependsOn":[],"notes":[],"journal":"The Lancet Oncology","year":2021,"doi":"10.1016/S1470-2045(20)30686-0","pmid":"33539729","authors":"Hoskin P, Popova B, Schofield O, et al.","paperType":"rct","findings":["Five-year local progression-free rate 89.9 percent (95% CI 85.5 to 93.1) after 24 Gy versus 70.4 percent (64.7 to 75.4) after 4 Gy.","Hazard ratio 3.46 (95% CI 2.25 to 5.33) at a median follow-up of 73.8 months."],"whatItMeans":"Confirms 24 Gy in 12 fractions as the optimal dose for indolent lymphoma when durable local control is the goal.","caveats":["Overall survival was not the endpoint and most patients had further systemic options at progression."],"changedPractice":true,"participants":548},"route":"/key-papers/paper-fort-long-term-follow-up-hoskin-lancet-oncol-2021/","neighbours":{"cancer":[{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"},{"id":"marginal-zone-lymphoma","kind":"cancer","name":"Marginal zone lymphoma","route":"/cancers/marginal-zone-lymphoma/"}],"trial":[{"id":"fort","kind":"trial","name":"FoRT","route":"/trials/fort/"}],"journal":[{"id":"lancet-oncology","kind":"journal","name":"The Lancet Oncology","route":"/journals/lancet-oncology/"}]}}